Why Zura Bio Limited’s (ZURA) Stock Is Down 5.55%
As of Thursday, October 08, Zura Bio Limited’s ZURA share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Commentary & Analysis
Why Zura Bio Limited’s (ZURA) Stock Is Up 7.45%
As of Wednesday, October 07, Zura Bio Limited’s ZURA share price has surged by 7.45%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Zura Bio Limited’s (ZURA) Stock Is Down 6.93%
As of Thursday, September 24, Zura Bio Limited’s ZURA share price has dipped by 6.93%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Zura Bio Limited’s (ZURA) Stock Is Down 5.76%
As of Wednesday, September 23, Zura Bio Limited’s ZURA share price has dipped by 5.76%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Zura Bio Limited’s (ZURA) Stock Is Down 6.43%
As of Tuesday, September 15, Zura Bio Limited’s ZURA share price has dipped by 6.43%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $383.3 | $242.6 | 35% |
|
| Shares Out (Mil) | 126.8 | 54.0 | 67% |
|
| Institutional Ownership | 83.8% | 93.1% | 52% |
|
| Float (Mil) | 50.7 | 41.4 | 47% |
|
| Beta | -0.02 | 0.95 | 6% |
|
| Avg Daily Volume (000s) | 2,327 | 633 | 83% |
|
| Price Change (52-week) |
(7.8%) | 50.0% | 46% |
|
| Growth | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.200) | ($0.773) | ($0.615) | |
| Month Ago EPS | ($0.203) | ($0.773) | ($0.583) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.185) | ($0.710) | ($0.500) | |
| Year/Year Chg | (3.4%) | (26.7%) | (19.9%) | |
| Financials | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($86) | ($44) | 12% |
|
| EPS (TTM) | ($1.087) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($78) | ($34) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $51 | $2 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $328 | $177 | 30% |
|
| Valuation | ZURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.93 | 2.33 | 51% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (46.2%) | (47.6%) | 12% |
|
| ROE | (53.1%) | (54.9%) | 15% |
|
| Liabilities to Assets | 7.6% | 29.3% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
Zura Bio Limited did not pass any screens on 10/9/2026.
